TABLE 1.
Characteristics of the cohort by clinical group.
|
CU n = 100 |
iRBD n = 15 |
MCI‐LB n = 37 |
DLB n = 70 |
p‐Value * | |
|---|---|---|---|---|---|
| Age, years | 68.76 (10.01) | 67.29 (7.85) | 68.69 (8.72) | 69.50 (8.47) | 0.848 |
| Males, n (%) [Link] , [Link] | 86 (86%) | 10 (67%) | 36 (97%) | 59 (84%) | 0.033 |
| APOE ε4, n (%) | 27 (29%) | 5 (36%) | 11 (30%) | 29 (42%) | 0.324 |
| Education, years | 15.57 (2.34) | 16.73 (3.13) | 16.03 (2.69) | 15.66 (3.05) | 0.406 |
| MMSE † | 29.02 (0.90) | 28.13 (1.13) | 27.27 (2.16) | 21.81 (5.72) | <0.001 |
| CDR‐SOB [Link] , [Link] | 0.06 (0.32) | 0.23 (0.62) | 1.66 (0.96) | 5.56 (3.27) | <0.001 |
| Chronic kidney disease, n (%) | 10 (10%) | 1 (67%) | 2 (5%) | 2 (3%) | 0.325 |
| Abnormal DaTSCAN, n (%) § | NA | 4 (40%) | 21 (72%) | 29 (91%) | 0.004 |
| Amyloid positive, n (%) † | 30 (30%) | 4 (27%) | 10 (27%) | 40 (57%) | <0.001 |
| PiB AD signature SUVr † | 1.53 (0.39) | 1.46 (0.25) | 1.53 (0.37) | 1.78 (0.48) | <0.001 |
| Tau positive, n (%) | 27 (27%) | 3 (21%) | 8 (31%) | 16 (40%) | 0.419 |
| Tau AD signature SUVr | 1.20 (0.09) | 1.19 (0.08) | 1.20 (0.10) | 1.27 (0.21) | 0.061 |
| Visual hallucinations, n (%) | NA | 0 (0%) | 5 (14%) | 39 (56%) | <0.001 |
| Cognitive fluctuations, n (%) | NA | 0 (0%) | 16 (43%) | 52 (74%) | <0.001 |
| Parkinsonism, n (%) | NA | 3 (20%) | 31 (84%) | 62 (89%) | <0.001 |
| RBD, n (%) | NA | 15 (100%) | 34 (92%) | 66 (94%) | 0.523 |
| Aβ 42/40 | 0.06 (0.02) | 0.06 (0.01) | 0.06 (0.02) | 0.06 (0.01) | 0.387 |
| GFAP [Link] , [Link] | 90.86 (47.88) | 98.36 (42.99) | 128.15 (76.33) | 154.28 (86.12) | <0.001 |
| NfL † | 22.46 (14.40) | 20.79 (5.33) | 22.15 (11.10) | 31.98 (21.40) | <0.001 |
| p‐tau 181 † | 1.88 (0.95) | 1.87 (0.86) | 2.19 (1.22) | 2.75 (1.42) | <0.001 |
Abbreviations: Aβ, amyloid beta; AD, Alzheimer's disease; APOE ε4, apolipoprotein E ε4 allele; CDR‐SOB, Clinical Dementia Rating‐Sum of Boxes; CU, cognitively unimpaired; DaTSCAN, dopamine active transporter scan; DLB, dementia with Lewy bodies; GFAP, glial fibrillary acidic protein; iRBD, isolated rapid eye movement (REM) sleep behavior disorder; MCI‐LB, mild cognitive impairment with Lewy bodies; MMSE, Mini‐Mental State Examination; NfL, neurofilament light; PiB, Pittsburgh compound B; p‐tau, phosphorylated tau; RBD, REM sleep behavior disorder; SUVr, standardized uptake value ratio.
* p‐values for differences between groups come from either ANOVA for continuous variables or a chi‐square test for categorical variables.
†Significant differences between DLB and CU (p < 0.05).
‡Significant differences between MCI‐LB and CU (p < 0.05).
§DaT scan was available for a total of 10 iRBDs, 29 MCI‐LBs, and 32 DLBs.